Use of trastuzumab for the treatment of early stage breast cancer

References

• Coleman MP, Gatta G, Verdecchia A (and the EUROCARE Working Group). EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann. Oncol.14, 128–149 (2003).
   PubMed Web of Science ®Google Scholar
• Schechter AL, Stern DF, Vaidyanathan L et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature312(5994), 513–516 (1984).
   PubMed Web of Science ®Google Scholar
• Schechter AL, Hung MC, Vaidyanathan L et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science229(4717), 976–978 (1985).
   PubMed Web of Science ®Google Scholar
• King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science229(4717), 974–976 (1985).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235(4785), 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244(4905), 707–712 (1989).
   PubMed Web of Science ®Google Scholar
• Coussens L, Yang-Feng TL, Liao YC et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science230(4730), 1132–1139 (1985).
   PubMed Web of Science ®Google Scholar
• Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature290(5803), 261–264 (1981).
   PubMed Web of Science ®Google Scholar
• Fendly BM, Winget M, Hudziak RM et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res.50(5), 1550–1558 (1990).
   PubMed Web of Science ®Google Scholar
• Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol.9, 1165–1172 (1989).
   PubMed Web of Science ®Google Scholar
• Konecny G, Fritz M, Untch M et al. HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. Breast Cancer Res. Treat.69, 53–63 (2001).
   PubMedGoogle Scholar
• Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene18, 2241–2251 (1999).
   PubMed Web of Science ®Google Scholar
• Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin. Oncol.27, 21–25 (2000).
   PubMed Web of Science ®Google Scholar
• Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu-overexpressing human breast cancer xenografts. Cancer Res.58, 2825–2831 (1998).
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol.17, 2639–2648 (1999).
   PubMed Web of Science ®Google Scholar
• Vogel CE, Cobleigh MA, Tripathy D et al. Efficacy and safety of Trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol.20, 719–726 (2002).
   PubMed Web of Science ®Google Scholar
• Mass R, Press M, Anderson S et al. Evaluation of clinical outcomes according to HER2 detection by FISH in women with metastatic breast cancer. Clin. Breast Cancer6(3), 240–246 (2005).
   PubMedGoogle Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344, 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Eisenhauer E. From the molecule to the clinic – inhibiting HER2 to treat breast cancer. N. Engl. J. Med.344, 841–842 (2001).
   PubMedGoogle Scholar
• Pegram MD, Pienkowski T, Nothfelt D et al. Results of two open-label multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J. Natl Cancer Inst.96, 759–769 (2004).
   PubMed Web of Science ®Google Scholar
• Rowland KM, Suman VJ, Ingle JN et al. NCCTG 98–32–52: randomized Phase II trial of weekly versus every 3-week administration of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol.22, 8 (2003).
   Google Scholar
• Robert NJ, Leyland-Jones B, Asmar L et al. Randomized Phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: an update including survival. Proc. Am. Soc. Clin. Oncol. Abstract 573 (2004).
   Google Scholar
• Leyland-Jones B, Gelmon K, Ayoub JP et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J. Clin. Oncol.21(21), 3965–3971 (2003).
   PubMed Web of Science ®Google Scholar
• Leyland-JonesB. Dose scheduling – herceptin. Oncology61(Suppl. 2), 31–36 (2001).
   PubMed Web of Science ®Google Scholar
• Baselga J, Carbonell X, Castaneda-Soto NJ et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J. Clin. Oncol.23(10), 2162–2171 (2005).
   PubMed Web of Science ®Google Scholar
• Yaziji H, Goldstein LC, Barry TS et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA291(16), 1972–1977 (2004).
   PubMed Web of Science ®Google Scholar
• Pauletti G, Dandekar S, Rong H et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J. Clin. Oncol.18(21), 3651–3664 (2000).
   PubMed Web of Science ®Google Scholar
• Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J. Clin. Oncol.20(14), 3095–3105 (2002).
   PubMed Web of Science ®Google Scholar
• Larsimont D, Di Leo A, Rouas G et al. HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice. Anticancer Res.22(4), 2485–2490 (2002).
   PubMed Web of Science ®Google Scholar
• Tubbs RR, Pettay JD, Roche PC et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J. Clin. Oncol.19(10), 2714–2721 (2001).
   PubMed Web of Science ®Google Scholar
• Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J. Clin. Oncol.19(10), 2587–2595 (2001).
   PubMed Web of Science ®Google Scholar
• Lebeau A, Deimling D, Kaltz C et al. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J. Clin. Oncol.19(2), 354–363 (2001).
   PubMed Web of Science ®Google Scholar
• Roche PC, Suman VJ, Jenkins RB et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J. Natl. Cancer Inst.94(11), 855–857 (2002).
   PubMedGoogle Scholar
• Paik S, Bryant J, Tan-Chiu E et al. Real-world performance of HER2 testing – National Surgical Adjuvant Breast and Bowel Project experience. J. Natl Cancer Inst.94(11), 852–854 (2002).
   PubMed Web of Science ®Google Scholar
• Ma Y, Lespagnard L, Durbecq V et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin. Cancer Res.11, 4393–4399 (2005).
   PubMed Web of Science ®Google Scholar
• Schlemmer BO, Sorensen BS, Overgaard J, Olsen KE, Gjerdrum LM, Nexo E. Quantitative PCR – new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization. Scand. J. Clin. Lab. Invest.64(5), 511–22 (2004).
   PubMed Web of Science ®Google Scholar
• Suo Z, Daehli KU, Lindboe CF, Borgen E, Bassarova A, Nesland JM. Real-time PCR quantification of c-erbB-2 gene is an alternative for FISH in the clinical management of breast carcinoma patients. Int. J. Surg. Pathol.12(4), 311–318 (2004).
   PubMedGoogle Scholar
• Gjerdrum LM, Sorensen BS, Kjeldsen E, Sorensen FB, Nexo E, Hamilton-Dutoit S. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. J. Mol. Diagn.6(1), 42–51 (2004).
   PubMed Web of Science ®Google Scholar
• Raab GH, Hoegel B, Biebl J et al. Chromogen in situ hybridisation (CISH) for HER2 assessment is highly concordant with FISH in core cut biopsies of primary T2 breast cancers. Proc. Am. Soc.Clin. Oncol.569 (2004).
   Google Scholar
• Vera-Roman JM, Rubio-Martinez LA. Comparative assays for the HER-2/neu oncogene status in breast cancer. Arch. Pathol. Lab. Med.128(6), 627–633 (2004).
   PubMed Web of Science ®Google Scholar
• Denoux Y, Arnould L, Fiche M et al. HER2 gene amplification assay: is CISH an alternative to FISH? Ann. Pathol.23(6), 617–622 (2003).
   PubMedGoogle Scholar
• The Nolvadex Adjuvant Trial Organization. Controlled trial of tamoxifen as adjuvant agent in management of early breat cancer. Lancet19, 257–261 (1983).
   Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353, 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Hortobagyi G. Trastuzumab in the treatment of breast cancer. N. Engl. J. Med.353, 1734–1736 (2005).
   PubMed Web of Science ®Google Scholar
• Smith I. HERA Trial updated results. Scientific Special Session. Am. Soc. Clin. Oncol. (2006).
   Google Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353, 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Perez E, Suman V, Davidson N et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. J. Clin. Oncol.ASCO Ann. Meeting Proc.23(16S), 556 (2005).
   Google Scholar
• Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer97, 2972–2977 (2003).
   PubMed Web of Science ®Google Scholar
• Clayton AJ, Danson S, Jolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br. J. Cancer91, 639–643 (2004).
   PubMed Web of Science ®Google Scholar
• Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J. Clin. Oncol.22, 3608–3617 (2004).
   PubMed Web of Science ®Google Scholar
• Kim C, Bryant J, Horne Z et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of deregulated cMYC in vivo. San Antonio Breast Cancer SymposiumAbstract 46 (2005).
   Google Scholar
• Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium Abstract 1 (2005).
   Google Scholar
• Joensuu H, Kellokumpu-Lehtinen P, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med.354(8), 808–820 (2006).
   Google Scholar
• Chien K. Herceptin and the heart – a molecular modifier of cardiac failure. N. Engl. J. Med.354(8), 789–790 (2006).
   PubMed Web of Science ®Google Scholar
• Mohsin S, Weiss H, Gutierrez C et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J. Clin. Oncol.23, 11, 2460–2468 (2005).
   PubMed Web of Science ®Google Scholar
• Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res.10, 5650–5655 (2004).
   PubMed Web of Science ®Google Scholar
• Buzdar A, Ibrahim N, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol.23(16), 3676–3685 (2005).
   PubMed Web of Science ®Google Scholar
• Wenzel C, Hussian D, Bartsch R et al. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J. Cancer Res. Clin. Oncol.130, 400–404 (2004).
   PubMedGoogle Scholar
• Hoffmann la Roche. Herceptin key clinical trials card, October (2004).
   Google Scholar
• Burstein H, Harris L, Gelman R et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J. Clin. Oncol.21(1), 46–53 (2003).
   PubMed Web of Science ®Google Scholar
• Hurley J, Doliny P, Reis I et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J. Clin. Oncol.24(12), 1831–1838 (2006).
   PubMed Web of Science ®Google Scholar
• Bines J, Murad A, Lago S et al. Multicenter Brazilian study of weekly docetaxel and trastuzumab as primary therapy in stage III, HER-2 overexpressing breast cancer. Proc. Am. Soc. Clin. Oncol.22, 67 (2003).
   Google Scholar
• Coudert B, Arnould L, Moreau L et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter Phase II trial. Ann. Oncol.17(3), 409–414 (2006).
   PubMed Web of Science ®Google Scholar
• Van Pelt AE, Mohsin S, Elledge RM et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin. Breast Cancer4, 348–353 (2003).
   PubMedGoogle Scholar
• Schiffhauer LM, Griggs JJ, Ahrendt GM et al. Docetaxel and trastuzumab as primary systemic therapy for HER-2/neu-overexpressing breast cancer. Proc. Am. Soc. Clin. Oncol.22, 242 (2003).
   Google Scholar
• Harris L, Burstein HJ, Gelman R et al. Preoperative trastuzumab and vinorelbine (HN) is a highly active, well-tolerated regimen for HER2 3+/FISH+ Stage II/III breast cancer. Proc. Am. Soc. Clin. Oncol.22, 22 (2003).
   Google Scholar
• Limentani SA, Brufsky AM, Erban JK et al. Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support. Br. Cancer Res. Treat.82, S55 (2003).
   Web of Science ®Google Scholar
• Seidman A, Hudis C, Pierri M et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol.20(5), 1215–1221 (2002).
   PubMed Web of Science ®Google Scholar
• Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 J. Clin. Oncol.23(31), 7811–7819 (2005).
   PubMed Web of Science ®Google Scholar
• Ozcelik C, Erdmann B, Pilz B et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl Acad. Sci. USA99(13), 8880–8885 (2002).
   PubMed Web of Science ®Google Scholar
• Ewer M, Lippman S. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J. Clin. Oncol.23(13), 2900–2902 (2005).
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan S, Linnane J. The other side of the coin. Br. Med. J.331, 1202–1203 (2005).
   PubMedGoogle Scholar
• Littlejohns P. Trastuzumab for early breast cancer: evolution or revolution? Lancet Oncol.7(1), 22–23 (2006).
   PubMedGoogle Scholar
• Neyt M, Albrecht A, Cocquyt VF. An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial. Ann. Oncol.17, 381–390 (2006).
   PubMed Web of Science ®Google Scholar
• Ismael G. Breast International Group Newsletter, Spring (2006).
   Google Scholar
• Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J. Clin. Oncol.18(11), 2349–2351 (2000).
   PubMed Web of Science ®Google Scholar
• Smith I. Trastuzumab for early breast cancer. Lancet367, 106–107 (2006).
   Google Scholar